[PDF][PDF] The cytokines of asthma
BN Lambrecht, H Hammad, JV Fahy - Immunity, 2019 - cell.com
Asthma is a chronic inflammatory airway disease associated with type 2 cytokines
interleukin-4 (IL-4), IL-5, and IL-13, which promote airway eosinophilia, mucus …
interleukin-4 (IL-4), IL-5, and IL-13, which promote airway eosinophilia, mucus …
Mast cells in inflammation and disease: recent progress and ongoing concerns
Mast cells have existed long before the development of adaptive immunity, although they
have been given different names. Thus, in the marine urochordate Styela plicata, they have …
have been given different names. Thus, in the marine urochordate Styela plicata, they have …
Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a …
S Diver, L Khalfaoui, C Emson, SE Wenzel… - The Lancet …, 2021 - thelancet.com
Background Tezepelumab is a human monoclonal antibody that blocks the activity of thymic
stromal lymphopoietin (TSLP), an epithelial cell-derived cytokine. In phase 2b and 3 studies …
stromal lymphopoietin (TSLP), an epithelial cell-derived cytokine. In phase 2b and 3 studies …
EAACI Biologicals Guidelines—Recommendations for severe asthma
Severe asthma imposes a significant burden on patients, families and healthcare systems.
Management is difficult, due to disease heterogeneity, co‐morbidities, complexity in care …
Management is difficult, due to disease heterogeneity, co‐morbidities, complexity in care …
Anti‐IL‐5 therapies for asthma
Background This is the second update of previously published reviews in the Cochrane
Library (2015, first update 2017). Interleukin‐5 (IL‐5) is the main cytokine involved in the …
Library (2015, first update 2017). Interleukin‐5 (IL‐5) is the main cytokine involved in the …
Type 2 inflammation in asthma—present in most, absent in many
JV Fahy - Nature Reviews Immunology, 2015 - nature.com
Asthma is one of the most common chronic immunological diseases in humans, affecting
people from childhood to old age. Progress in treating asthma has been relatively slow and …
people from childhood to old age. Progress in treating asthma has been relatively slow and …
Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations
Background Short-term targeted treatment can potentially prevent fall asthma exacerbations
while limiting therapy exposure. Objective We sought to compare (1) omalizumab with …
while limiting therapy exposure. Objective We sought to compare (1) omalizumab with …
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
Background Some patients with severe asthma have recurrent asthma exacerbations
associated with eosinophilic airway inflammation. Early studies suggest that inhibition of …
associated with eosinophilic airway inflammation. Early studies suggest that inhibition of …
Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics
CM Porsbjerg, A Sverrild, CM Lloyd… - European …, 2020 - Eur Respiratory Soc
Monoclonal antibody therapies have significantly improved treatment outcomes for patients
with severe asthma; however, a significant disease burden remains. Available biologic …
with severe asthma; however, a significant disease burden remains. Available biologic …
Omalizumab for asthma in adults and children
R Normansell, S Walker, SJ Milan… - … of systematic reviews, 2014 - cochranelibrary.com
Background Asthma is a respiratory (airway) condition that affects an estimated 300 million
people worldwide and is associated with significant morbidity and mortality. Omalizumab is …
people worldwide and is associated with significant morbidity and mortality. Omalizumab is …